Renerve Limited · ASX:RNV
Renerve — Earnings Presentation (November 2025)
21 slides from Renerve's earnings presentation, Nov 10, 2025
Slide 1: Sales & Marketing Update – Transforming Nerve Repair Through Science
For personal use only ASX:RNV Sales & Transforming Nerve Marketing Update Repair Through Science ReNerve Board meeting | July 2025 ReNerve Quarterly Webinar presentation | November 2025 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd Disclaimer: No representation or warranty, express or implied, is made by the Company (Company) to provide general information about the Company. The information in this that the material
Slide 3: Executive Summary
Executive Summary Development of Novel Nerve Repair & Regeneration Products For personal use only ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial demand. Expanding Product Portf
Slide 4: Quarter Highlights
Quarter Highlights For personal use only Sales up 38% to corresponding qtr Launch of Empliq - Growing year on year Product Range Launch of two new product ranges Revenue up 38% qtr on qtr Closing cash of $3.27M Launched Dermal and 3 Amniotic Tissue Product Ranges Small team in the US as we build our
Slide 5: Company Portfolio
Company Portfolio Product Product Commercial On Market R&D Development Development For personal use only Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental 5
Slide 6: Global Nerve Repair Biomaterials Market
2031 Target USD$6.0Bn USD$6.19Bn Market For personal use only The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. Our Target Markets Global Nerve Repair Biomaterial Market 2025 Dermal and Amniotic Tissue U
Slide 7: ReNerve's Nerve Opportunity
ReNerve’s Nerve Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve For personal use only • Used on damaged or transected • Improved Nerve Cuff developed from • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure s
Slide 8: Product Range
For personal use only 01 Product Range 8
Slide 9: Empliq Product Portfolio
Empliq Product Portfolio For personal use only Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane Double-layer amniotic Placental allograft including Deep-layer dermal matrix allograft membrane allograft amniotic membrane and chorion Clinical V
Slide 10: Sales and Marketing Update: US Market Expanded
Sales and Marketing Update US Market Expanded Distribution Channels Robust Portfolio For personal use only • Expanded to 21 distributors across the US • Full logistics, warehousing and invoicing in place • Distributors will sell the ReNerve product ranges • Will add additional products as they come
Slide 11: Ex-US Sales & Marketing
Ex-US Sales & Marketing Sales Highlights ReNerve Distribution For personal use only Indian submission completed and in final Government review. Market valued at USD$115M and growth at 18+%* Working with the local Indian partner India Asia MIDDLE EAST to engage with hospitals and surgeons with extens
Slide 12: Nerve Cuff
For personal use only 02 Nerve Cuff 12
Slide 13: Nerve Cuff Key Features
Key Features ReNerve’s “Align” 1 Product Clinical Study For personal use only • Protects nerves during recovery post peripheral nerve repair • Great handling characteristics and absorbed within 6 Patient Results 2 months Definitive clinical study on using NervAlign Nerve Patient Benefit Cuff for ner
Slide 14: The "Align" Study
The “Align” Study Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair and surgical neurolysis to show the benefit of protecting the nerve post nerve Comparison of Patient Pre & Post For personal use only repair surgery. Surgery Pain Score 7.1 7.1 Study Design:
Slide 15: Conduit Update
For personal use only 03 Conduit Update 15
Slide 16: Conduit Update
Conduit For personal use only Update 1 Currently doing scale up manufacturing and validation runs 2 Able to make it commercially – moving to commercial material production
Slide 17: Nerve Guide Matrix (Graft)
04 For personal use only Nerve Guide Matrix (Graft) 17
Slide 18: Key Features & Guide Matrix Benefits
Key Features & Guide Matrix Benefits ReNerve Nerve Guide Matrix offers many benefits, including: For personal use only Product Current Options - Doesn’t create secondary surgical site; - Stored at room temperature, removing • Harvesting patients own storing issues; • The NervAlign® Neve Guide Matrix
Slide 19: Near Term Milestones – 2025/2026
Near Term Milestones – 2025/2026 For personal use only 1H 2025 Q4 2025/Q1 2026 Near Term NervAlign® Nerve Conduit into Market 27 February 2025 Nerve Guide Matrix GMP (Q4 2025/Q1 2026) Partnership Signed for Mexico Market production Growing the EmpliQ brand ReNerve ‘Align’ Study 7 March 2025 data R&D
Slide 20: Investment Highlights
Investment Highlights For personal use only In Market Product Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Product offering promotes nerve injury Nerve repair biomaterials and related commercial sales post FDA market clearance, recovery and regrowth leading to faster mark
Slide 21: Contact
For personal use only ASX:RNV Contact ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia 21